Related Experiment Video
Updated: May 28, 2026
11:08
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
Published on: June 22, 2012
Microfluidics for Blood Disorders and Hematological Disease Monitoring and Modeling
Mengjia Hu1,2,3,4, Nathan Henderson1,2,3,4, Steven A Soper1,2,3,4,5,6
1Department of Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
International Journal of Molecular Sciences
|May 27, 2026
Summary
Microfluidic technologies offer advanced, minimally invasive methods for diagnosing and monitoring blood disorders. These lab-on-a-chip devices enable precise analysis of liquid biopsies, improving accessibility and patient care for hematologic conditions.
Area of Science:
- Biomedical Engineering
- Hematology
- Microfluidics
Background:
- Blood disorders pose significant global health challenges, affecting vital physiological functions like oxygenation and coagulation.
- Hematologic malignancies necessitate accurate diagnosis and continuous monitoring for effective management.
- Traditional diagnostic methods often involve invasive procedures like bone marrow aspiration.
Purpose of the Study:
- To review the advancements in microfluidic technologies for the diagnosis and monitoring of blood disorders.
- To highlight the potential of microfluidics in analyzing liquid biopsy markers for minimally invasive disease assessment.
- To discuss the application of microfluidic devices in modeling blood disorders and recapitulating the blood cancer microenvironment.
Main Methods:
- Utilizing microfluidic assays for the isolation and characterization of liquid biopsy markers (rare cells, extracellular vesicles, cell-free molecules).
- Developing microfluidic vascular models to replicate physiological conditions for assessing blood component behavior (deformability, aggregation, clot formation).
- Employing lab-on-a-chip technologies for high-throughput analysis of blood, plasma, and urine samples.
Main Results:
- Microfluidic devices enable high-throughput analysis of liquid biopsies for detecting disease-specific biomarkers.
- These technologies offer a minimally invasive alternative to traditional bone marrow procedures.
- Microfluidic vascular models provide quantitative assessments of blood cell dynamics and clot formation.
- Organ-on-chip models are being developed to simulate blood cancer microenvironments.
Conclusions:
- Microfluidics presents a transformative approach to blood disorder diagnostics and monitoring, enhancing precision and accessibility.
- Lab-on-a-chip technologies facilitate biomarker validation and clinical translation for improved patient outcomes.
- Future directions include leveraging microfluidics for personalized medicine and advanced mechanistic investigations in hematology.
